Nude mouse bearing human bladder cancer exhibits similar growth characteristics as human bladder cancer and therfore is a good simulation model in the research of the biological behaviors of human bladder cancer. To explore the initiation, development, prognosis and biological behavior of human bladder cancer,and to develop intravesical biological agents and antitumor drugs with improved strategies for prevention and treatment of bladder cancer, it is essential to establish human bladder tumor-bearing nude mice for basic and clinical researches. This is a review of the current status of the application of human bladder tumor-bearing nude mice.

Objective: To assess the prevalence of HIV infection and related factors in men who have sex with men (MSM) living for ≤5 years in Wenzhou of Zhejiang province. Methods: MSM who were aged ≥16 years, had lived in Wenzhou for ≥3 months and had anal sex and/or oral sex with men in the last 12 months were recruited through respondent-driven sampling (RDS) from February to October in 2015. The MSM recruited completed a questionnaire for the information collection on socio-demographic characteristics, sexual behavior, awareness of HIV and related intervention, mental health status. Blood samples were collected from them for serological detection of HIV and syphilis antibodies. Software SPSS 18.0 was used to analyze HIV infection and related factors. Results: A total of 454 MSM were investigated, 108 of them (23.7%) were HIV positive. There were 267 MSM who lived in Wenzhou for ≤5 years, and 73 of them (27.3%) were HIV positive. Most of them were workers and commercial servants aged ≥25 years with personal monthly income <4 000 yuan and educational level of junior high school or below. According to multiple logistics regression analysis, age of 25-68 years old (OR=12.19, 95%CI: 2.29-65.02), heterosexual behavior in recent 6 months (OR=0.42, 95%CI: 0.18-0.96), believing it was possible to be infected with HIV (OR=0.06, 95%CI: 0.01-0.95), believing it was impossible to be infected with HIV (OR=0.03, 95%CI: 0.01-0.35) and syphilis status (OR=3.32, 95%CI: 1.05-10.52) were the risk factors associated with HIV infection. Conclusion: Compared with MSM who lived in Wenzhou for >5 years, MSM who lived in Wenzhou for ≤5 years had higher HIV infection rate and higher prevalence of risk behavior. It is necessary to conduct targeted intervention among them.
Adult ; Aged ; HIV Infections/epidemiology* ; Homosexuality, Male/statistics & numerical data* ; Humans ; Male ; Middle Aged ; Sexual Behavior ; Surveys and Questionnaires

Objective: To compare the clinical efficacy of icotinib and gefitinib in the treatment of advanced(stage Ⅳ) lung adenocarcinoma patients with epidermal growth factor receptor(EGFR) sensitive gene mutation. Methods: Fifty-four advanced(stage Ⅳ) lung adenocarcinoma patients with EGFR sensitive gene mutation were selected.According to the random number table method, the patients were divided into two groups, with 27 cases in each group.The icotinib group received icotinib hydrochloride targeted therapy, and the gefitinib group was orally given gefitinib.The clinical efficacy, quality of life score, adverse reactions, progression free survival(PFS) were compared between the two groups. Results: There were no statistically significant differences in clinical curative effect between the two groups[complete remission(0 cases vs.0 cases), partial remission(9 cases vs.8 cases), stable(12 cases vs.14 cases), progress disease(6 cases vs.5 cases), objective response rate(33.3% vs.29.6%), disease control rate(77.8% vs.81.5%), Z=1.060, χ²=0.143, 0.100, all P>0.05]. After treatment, the differences of body function, social function, psychological function, common symptoms and side effects, specific modules in the gefitinib group were not statistically significant compared with those before treatment(t=1.402, 1.199, 1.840, 1.860, 1.275, all P>0.05). The icitinib group had better body function, psychological function, common symptoms, side effects and specific modules than before treatment(t=2.525, 3.335, 4.477, 3.778, all P<0.05). The psychological function, common symptoms and side effects, specific module life quality scores in the icotinib group were (39.72±4.23)points, (38.84±4.67)points, (38.94±4.56)points, respectively, which were higher than (37.08±5.14)points, (35.48±5.02)points, (35.85±4.97)points in the gefitinib group(t=2.061, 2.546, 2.380, all P<0.05). The incidence rate of Ⅰ-Ⅱ grade adverse reactions between the two groups had no statistically significant difference (χ²=4.667, P>0.05). The incidence rate of Ⅲ-Ⅳ grade adverse reactions of the icotinib group was 7.4%, which was lower than 25.9% of the gefitinib group(χ²=9.000, P<0.05). The total incidence rate of adverse reactions of the icotinib group was 40.7%, which was significantly lower than 70.4% of the gefitinib group(χ²=25.694, P<0.05). There was no statistically significant difference in mean PFS between the two groups in the 19delete mutation of EGFR gene(t=0.795, P>0.05). The average PFS of the icotinib group under EGFR gene 21L858R mutation was (14.62±3.85)months, which was longer than (10.73±5.61)months of the gefitinib group(t=2.971, P<0.05). Conclusion Icotinib, gefitinib in the treatment of advanced(stage Ⅳ) lung adenocarcinoma patients with EGFR sensitive gene mutation has similar clinical effect, but icotinib has higher safety, better tolerability, and can significantly improve the quality of life of patients, prolong the EGFR mutation of the 21L858R gene under the survival of patients.

Radiotherapy is a critical approach for the comprehensive treatment of non-small cell lung cancer.Deep understanding of the individualized radiosensitivity of lung cancer patients plays a pivotal role in the selection of radiotherapy dosage and regime and establishment of comprehensive therapeutic strategies.Currently,multiple researchers have identified a variety of biomarkers in predicting the radiosensitivity of lung cancer patients.In this article,research progress on the biomarkers in predicting radiosensitivity of non-small cell lung cancer was reviewed.